A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase IBiomarker/Laboratory analysis, Treatment18 and overA8081001
NCI-2009-01775, PROFILE 1001, NCT00585195

Trial Description

Summary

PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor

cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor

tyrosine kinase inhibitors. This compound is also an inhibitor of the anaplastic lymphoma

kinase (called ALK) tyrosine kinase and ROS receptor tyrosine kinases. This research study

is the first time PF-02341066 will be given to people. PF-02341066 is taken by mouth

daily.

Eligibility Criteria

Inclusion Criteria:

Adequate blood cell counts, kidney function, liver function and Eastern Cooperative

Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG

score of 2 may be allowed on a case-by-case basis)

Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients

with non-measurable disease may enter on a case-by-case basis); not required for DDI

sub-studies.

Advanced malignancies (except leukemias), histologically proven at diagnosis;

Histologically confirmed advanced malignancies that are known to be sensitive to

PF-03241066 inhibition, e.g. ALK, c-MET and ROS

Exclusion Criteria:

Active or unstable cardiac disease or heart attack within 3 months of starting study

treatment

Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma

Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of

starting study treatment, depending on the patient cohort

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

Pfizer Inc

    Trial Sites

    U.S.A.

    California
    Orange

    UC Irvine Health/Chao Family Comprehensive Cancer Center

    Sai-Hong Ignatius Ou
    Principal Investigator

    Colorado
    Aurora

    University of Colorado Cancer Center - Anschutz Cancer Pavilion

    Ross Camidge
    Principal Investigator

    Illinois
    Chicago

    University of Chicago Comprehensive Cancer Center

    Ravi Salgia
    Principal Investigator

    Massachusetts
    Boston

    Beth Israel Deaconess Medical Center

    Daniel Chang Cho
    Principal Investigator

    Brigham and Women's Hospital

    Geoffrey Ira Shapiro
    Principal Investigator

    Dana-Farber Cancer Institute

    Geoffrey Ira Shapiro
    Principal Investigator

    Dana-Farber Harvard Cancer Center

    Jeffrey W. Clark
    Principal Investigator

    Charlestown

    Massachusetts General Hospital

    Jeffrey W. Clark
    Principal Investigator

    Michigan
    Detroit

    Barbara Ann Karmanos Cancer Institute

    Ulka N. Vaishampayan
    Principal Investigator

    North Carolina
    Chapel Hill

    University of North Carolina at Chapel Hill

    Jared Weiss
    Principal Investigator

    Ohio
    Columbus

    Ohio State University Comprehensive Cancer Center

    Gregory A. Otterson
    Principal Investigator

    Pennsylvania
    Pittsburgh

    University of Pittsburgh Cancer Institute (UPCI)

    Mark Anthony Socinski
    Principal Investigator

    Tennessee
    Nashville

    Vanderbilt University/Ingram Cancer Center

    Vicki L. Keedy
    Principal Investigator

    Link to the current ClinicalTrials.gov record.
    NLM Identifer NCT00585195

    Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.